Document is current
Any future updates will be listed below
-
Authors
Blume, John E. http://orcid.org/0000-0003-3026-953X
Manning, William C.
Troiano, Gregory
Hornburg, Daniel
Figa, Michael
Hesterberg, Lyndal
Platt, Theodore L.
Zhao, Xiaoyan
Cuaresma, Rea A.
Everley, Patrick A.
Ko, Marwin
Liou, Hope
Mahoney, Max
Ferdosi, Shadi http://orcid.org/0000-0003-2933-8809
Elgierari, Eltaher M.
Stolarczyk, Craig
Tangeysh, Behzad
Xia, Hongwei
Benz, Ryan
Siddiqui, Asim
Carr, Steven A.
Ma, Philip
Langer, Robert http://orcid.org/0000-0003-4255-0492
Farias, Vivek http://orcid.org/0000-0002-5856-9246
Farokhzad, Omid C. http://orcid.org/0000-0003-2009-270X
- License Information
-
More Information
Article History
Received: 14 December 2019
Accepted: 2 June 2020
First Online: 22 July 2020
Competing interests
: O.C.F. has financial interest in Selecta Biosciences, Tarveda Therapeutics, and Seer. R.L. is involved, compensated or uncompensated, in the entities listed in Supplementary Note 2. V.F. has financial interest in Celect and Seer. S.C. has financial interest in Kymera, PTM BioLabs, Pfizer, Biogen, and Seer. J.E.B, W.C.M., G.T., M.F., L.H., T.L.P., X.Z., R.A.C, P.A.E., M.K., H.L., E.M.E., M.M., S.F., C.S., R.B., B.H., H.X., D.H., A.S., and P.M. have financial interest in Seer. Only Seer, and no other companies mentioned here, was involved in the study design, data collection and analysis, and manuscript writing/editing.
